Infectious complications of EBUS-TBNA: A nested case-control study using 10-year registry data
Noeul Kang1, Sun Hye Shin1, Hongseok Yoo1
1Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Lung Cancer (Amsterdam, Netherlands)
|September 4, 2021
Summary
Infectious complications from endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) are rare but linked to necrotic lesions and esophageal procedures. Patients experiencing complications may be less likely to start anti-cancer treatment.
Area of Science:
- Pulmonology
- Interventional Pulmonology
- Medical Procedures
Background:
- Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a standard diagnostic procedure.
- Infectious complications following EBUS-TBNA are not well-characterized.
Purpose of the Study:
- To determine the incidence and risk factors of infectious complications after EBUS-TBNA.
- To evaluate the clinical course of these complications, including their impact on anti-cancer therapy.
Main Methods:
- A nested case-control study was conducted on 6826 patients undergoing EBUS-TBNA.
- Infection was defined by clinical symptoms and imaging; risk factors were identified using multivariate logistic regression.
Main Results:
- The incidence of infectious complications was 0.48% (33/6826), including pneumonia and mediastinal infections.
- Necrotic target lesions on CT scans and esophageal EBUS-TBNA procedures were independent risk factors.
- Patients with infectious complications showed a trend towards refusing anti-cancer treatment, though treatment onset was not delayed.
Conclusions:
- Infectious complications of EBUS-TBNA are infrequent but associated with specific procedural and imaging findings.
- Healthcare providers should be vigilant for complications in cases with necrotic lesions or esophageal access.
- Further research is needed to confirm the impact of infectious complications on anti-cancer treatment adherence.


